Novo Nordisk A/S has agreed to settle a U.S. probe of its marketing of diabetes drugs that allegedly included disguising salespeople as medical educators and paying kickbacks to persuade doctors to prescribe its medicines. The allegations were disclosed when a whistle-blower lawsuit was unsealed by a judge.
The U.S. Justice Department investigation, which began in 2011, focused on claims of illegal marketing of the Danish insulin supplier’s top-selling Victoza diabetes drug and other products, according to Novo’s 2016 annual report.
